Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diabetes drug discovery company Akesis Pharmaceuticals, has secured its fourth US patent, covering compositions and methods of treatment for diabetes and other glucose metabolism disorders.
Subscribe to our email newsletter
“We believe this patent, which combines Akesis’ unique formula of anti-diabetic trace minerals with the widely prescribed sulfonylurea class of medications is an important step in our mission to develop innovative formulations for the treatment of diabetes,” said Edward Wilson, president and CEO of Akesis Pharmaceuticals.
The company’s broad intellectual property portfolio of several US-issued patents encompasses compositions and uses of matter, delivery in multiple consumer-oriented forms, delivery alone and in combination with other agents (including many classes of diabetes therapeutic agents), and methods for treatment and diagnoses.
Akesis’ proprietary formulations have shown promise in lowering and controlling blood glucose levels in patients with type 2 diabetes and initial studies suggest that several of Akesis’ patented formulations have the potential to be superior to drugs currently on the market for the treatment of diabetes and other glucose metabolism disorders.